Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.